How to access Ctexli for cerebrotendinous xanthomatosis from Qatar: 2026 pathway via HMC adult neurology and Sidra Medicine paediatric | Reserve Meds
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
Qatar's metabolic-genetics infrastructure is anchored in Hamad Medical Corporation (HMC) for adult neurology and Sidra Medicine for paediatric. Sidra runs the regional paediatric metabolic-genetics service of record and confirms paediatric CTX cases for the GCC. Adult CTX is managed at HMC neurology. The 2026 question is how to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement.
Why Ctexli, why now
Ctexli (chenodiol, chenodeoxycholic acid) received US FDA approval in February 2024 as the first labelled treatment for cerebrotendinous xanthomatosis (CTX) in adult and paediatric patients. Mirum Pharmaceuticals is the US sponsor. CTX is a rare autosomal recessive bile-acid synthesis disorder caused by biallelic pathogenic variants in CYP27A1, the gene encoding sterol 27-hydroxylase. The enzyme deficiency disrupts bile-acid synthesis and leads to accumulation of cholestanol and bile alcohols in tissues. Untreated CTX manifests with chronic diarrhoea, juvenile cataracts, tendon xanthomas, premature atherosclerosis, and progressive neurologic deterioration including cerebellar ataxia, pyramidal signs, dystonia, peripheral neuropathy, psychiatric features, and cognitive decline. Most patients develop neurologic symptoms in the second or third decade if untreated.
The 2026 question for a Qatar patient with CTX is how to source Ctexli now that there is finally a labelled treatment. With FDA approval less than 24 months ago, Ctexli is not yet registered with the Ministry of Public Health (MoPH), so the pathway is named-patient personal-import authorisation under MoPH.
What Ctexli is, in plain language
Ctexli is an oral chenodiol capsule. Mechanistically it replaces the missing bile acid (chenodeoxycholic acid) and restores feedback suppression of the upstream cholesterol-to-bile-acid pathway, thereby reducing the accumulation of cholestanol that drives tissue damage in CTX. Ctexli does not reverse pre-existing neurologic damage. It slows or halts progression, with strongest benefit when initiated before significant neurologic deterioration. Dosing is weight-based, given orally three times daily with food, lifelong.
Access pathway in Qatar
Qatar's Ministry of Public Health (MoPH), through the Department of Pharmacy and Drug Control (DPDC), regulates medicine registration, import licensing, and pharmacovigilance under the Medicines Law (Decree No. 3 of 1983, as amended). Ctexli is not currently MoPH-registered. Access runs through the MoPH named-patient personal-import authorisation, filed by the treating clinician at Hamad Medical Corporation (HMC) adult neurology or Sidra Medicine paediatric metabolic-genetics. Sidra runs the regional paediatric metabolic-genetics service of record and confirms paediatric CTX cases for the GCC; many adult genetic confirmations also flow through Sidra.
The treating neurologist or metabolic specialist submits the named-patient import application documenting the biallelic CYP27A1 confirmation, elevated plasma cholestanol, neurological status, and requested dose and supply quantity. MoPH reviews and issues an import authorisation per shipment. Reserve Meds sources Ctexli from a US DSCSA-compliant specialty wholesaler or an EU-licensed supplier and arranges shipping to Hamad International Airport.
Eligibility at a Qatar metabolic-genetics or neurology clinic
Ctexli eligibility requires biallelic pathogenic variants in CYP27A1 on molecular genetic testing plus elevated plasma cholestanol (typically more than five-fold above the upper limit of normal). The treating clinician documents baseline neurological examination, MRI white-matter findings, baseline liver function, and any systemic features (tendon xanthomas, juvenile cataracts, chronic diarrhoea, premature atherosclerosis, psychiatric features). Paediatric and many adult genetics confirmations run through Sidra Medicine metabolic-genetics; adult management runs through HMC adult neurology.
Documentation required
The patient and physician should be prepared to provide: a current Qatar ID or passport; the molecular genetic report confirming biallelic CYP27A1 variants; recent plasma cholestanol levels; baseline neurological examination notes; recent brain MRI (with attention to dentate nucleus and white-matter signal); recent liver function tests; documentation of prior empiric chenodeoxycholic acid use, if any; the treating physician's prescription on hospital letterhead; the clinical justification letter; the MoPH named-patient import application; and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US or EU export documentation, manufacturer pedigree, and customs packet.
Costs and funding considerations
The annual cost band for Ctexli in Qatar is USD 150,000 to 220,000 per patient (QAR 550,000 to 800,000), weight-dependent, lifelong. Pre-approval, CTX patients in the region were typically maintained on compounded chenodeoxycholic acid at substantially lower cost; FDA-approved Ctexli carries a manufacturer premium. MoPH coverage for rare-disease imports follows Qatar's national rare-disease policy case-by-case for Qatari nationals with documented eligibility and neurological progression risk. Private insurance coverage for an unregistered ultra-orphan agent is unusual. Most non-Qatari families self-fund or co-fund.
Typical timeline
Weeks 0 to 4: confirm diagnosis at Sidra (paediatric) or HMC (adult), prescription preparation, MoPH import filing. Weeks 4 to 8: shipment arrival at Hamad International Airport, initiation under metabolic-genetics or neurology supervision, baseline labs documented. Weeks 8 to 24: cholestanol trend, liver function, tolerability monitoring. Months 6 and 12: full metabolic-neurologic reassessment, repeat plasma cholestanol, and brain MRI white-matter assessment.
When Ctexli is the wrong drug
Without biallelic CYP27A1 pathogenic variants, the diagnosis is not CTX and Ctexli is not indicated. Normal plasma cholestanol calls the CTX diagnosis into question; pursue alternative metabolic and neurogenetic workup. Advanced neurologic damage in untreated patients means the realistic goal is stabilisation rather than reversal; family counselling should reflect this. Pregnancy data are limited; contraception is required for women of childbearing potential. Significant hepatic dysfunction requires careful dose adjustment.
Frequently asked questions
- Is the pathway legal in Qatar? Yes. It operates under MoPH/DPDC named-patient personal-import authorisation under the Medicines Law.
- Will MoPH or my insurance cover Ctexli? Qatari nationals may secure MoPH rare-disease case-by-case support; private insurance coverage for ultra-orphan agents is unusual.
- How long does treatment continue? Lifelong. CTX is a chronic genetic disease.
- Can I use generic chenodeoxycholic acid instead? Empirically yes in some jurisdictions, and many CTX patients were maintained on it pre-Ctexli; however, Ctexli is the FDA-approved labelled product with quality and supply assurance. The treating clinician decides.
- What if Ctexli is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.
- Can my child be treated? Yes; Ctexli is FDA-approved for paediatric patients. Paediatric cases in Qatar are typically managed at Sidra Medicine.
Closing
Reserve Meds runs the Ctexli supply file from the HMC adult-neurology or Sidra paediatric metabolic-genetics referral through MoPH named-patient authorisation, US or EU sourcing, and delivered supply. Clinical decisions remain with your treating metabolic specialist or neurologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating metabolic specialist or neurologist.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.